Financials
Financial year 2025
JANPHARMA from Buggenhout, company number BE0539740563, closed financial year 2025 with a result of € 46,550 after tax. For that financial year JANPHARMA recorded a gross margin of € 90,204 and equity of € 321,854. Compared with financial year 2024, the result moved from € 88,326 to € 46,550. The company is profitable. The company holds a healthy buffer. Debts are under control. The most recent annual accounts were filed with the National Bank of Belgium on March 23, 2026.
€ 321,854
▼ 3% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 46,550
▼ 47% vs 2024
Profit after tax over the fiscal year.
€ 56,385
▼ 43% vs 2024
Cash and bank balances on the last day of the fiscal year.
€ 52,267 paid out
More than the year’s profit went to the shareholders; reserves fell.
People and assets in 2025
€ 1,197
▼ 25% vs 2024
Book value of vehicles, furniture and equipment.
Debts at end 2025
€ 566,841
▼ 10% vs 2024
€ 64,156 is repaid this year. At this pace the long-term loan is gone in ≈ 9 years.
€ 896
▲ 16% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 23,278
▲ 39% vs 2024
Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 86,412 | € 73,624 | € 96,426 | € 90,204 | ▼ 6% |
| Profit after taxes | € 131,837 | € 29,528 | € 88,326 | € 46,550 | ▼ 47% |
| Equity | € 263,626 | € 270,306 | € 330,204 | € 321,854 | ▼ 3% |
| Total debts | € 882,403 | € 825,000 | € 793,944 | € 789,915 | ▼ 1% |
| Cash | € 19,522 | € 8,846 | € 98,291 | € 56,385 | ▼ 43% |
| Retained profit | € 245,076 | € 251,756 | € 311,654 | € 303,304 | ▼ 3% |
| Dividend | € 56,266 | € 22,848 | € 28,428 | € 52,267 | ▲ 84% |
| Bank debt | € 771,095 | € 697,634 | € 627,578 | € 566,841 | ▼ 10% |
| Balance sheet total | € 1,146,029 | € 1,095,306 | € 1,124,148 | € 1,111,769 | ▼ 1% |
Key figures of JANPHARMA, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to JANPHARMA?
What happened at JANPHARMA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 46,550 (▼ 47% vs 2024). Source: NBB ↗
- New establishment in Buggenhout. KBO
- Start of the company according to the CBE. KBO
- Jan Heyvaert became a director. NBB
In short
From € 131,837 profit in 2022 to € 46,550 profit in 2025.
Paid € 88,901 in corporate taxes since 2022.
Best year ever: 2022, with € 131,837 profit.
Paid out € 159,809 in dividends to the owners in total.
Management
Behind JANPHARMA is Jan Heyvaert. It owns 45% of Opniphar itself.
Directors
According to the 2025 annual accounts
since 2013
Establishments
Establishment units
Physical locations of this company
Broekstraat 28
9255 Buggenhout
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 2 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0539.740.563
- VAT number
- BE 0539.740.563
- Registered office
- Broekstraat 28, 9255 Buggenhout
- Names & denominations
- JANPHARMA
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 30 September 2013
- Peppol
- Active · Active since 24 Nov 2023
- Activities · NACE
Activiteiten van holdings
Holdings
Overige dienstverlenende activiteiten op het gebied van informatie
Overige dienstverlenende activiteiten op het gebied van informatie, n.e. g.